Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
ICX-101
i
Other names:
ICX-101
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Twitter
Trials
Company:
Incurix, National Cancer Center
Drug class:
MYC inhibitor
Related drugs:
‹
GT19077 (14)
omacetaxine mepesuccinate (3)
WB100 (3)
PLX51107 (2)
RRx-001 (2)
10058-F4 (1)
MYCi975 (1)
OMO-103 (1)
GT19077 (14)
omacetaxine mepesuccinate (3)
WB100 (3)
PLX51107 (2)
RRx-001 (2)
10058-F4 (1)
MYCi975 (1)
OMO-103 (1)
›
Associations
(1)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
MYC overexpression
Small Cell Lung Cancer
MYC overexpression
Small Cell Lung Cancer
ICX-101
Sensitive: D – Preclinical
AACR 2023 - 1 week (New D)
ICX-101
Sensitive
:
D
AACR 2023 - 1wk
ICX-101
Sensitive: D – Preclinical
AACR 2023 - 1 week
ICX-101
Sensitive
:
D
AACR 2023 - 1 week - (New D)
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login